Results 151 to 160 of about 27,650 (185)
Some of the next articles are maybe not open access.
Pulmonary Lymphoid Neogenesis in Idiopathic Pulmonary Arterial Hypertension
American Journal of Respiratory and Critical Care Medicine, 2012Abstract Rationale Patients with idiopathic pulmonary arterial hypertension (IPAH) present circulating autoantibodies against vascular wall components. Pathogenic antibodies may be generated in tertiary (ectopic) lymphoid tissues (tLTs).
Frédéric Perros +2 more
exaly +5 more sources
Iloprost for idiopathic pulmonary arterial hypertension
Expert Review of Cardiovascular Therapy, 2005Idiopathic pulmonary arterial hypertension is a rare but serious and life-threatening disease that leads to right heart failure and death within 2.8 years without specific treatment. This review focuses on the stable prostacyclin analog iloprost, its biologic action and pharmacology and, finally, on its clinical development, efficacy and safety in ...
Juergen Bèhr
exaly +3 more sources
Idiopathic Pulmonary Arterial Hypertension Misdiagnosed as Asthma
Journal of Asthma, 2007Idiopathic pulmonary arterial hypertension (IPAH) is a rare disorder that is progressive and often leads to right heart failure if left untreated. Because of the vague nature of symptoms at presentation, IPAH may take several months to diagnose. The most common presenting complaint in patients with IPAH is dyspnea with exertion, which is also commonly ...
Don Hayes
exaly +3 more sources
Phenotypes of idiopathic pulmonary arterial hypertension [PDF]
The Lancet Respiratory Medicine, 2022 info:eu-repo/semantics ...
Alejandro, Cruz-Utrilla +4 more
+7 more sources
Idiopathic Pulmonary Arterial Hypertension
Seminars in Respiratory and Critical Care Medicine, 2013Idiopathic pulmonary arterial hypertension (IPAH), formerly called primary pulmonary hypertension, is a rare disease (incidence and prevalence rates of approximately one and six cases per million inhabitants, respectively) with different clinical phenotypes.
Rogerio, Souza +2 more
openaire +2 more sources
Idiopathic pulmonary arterial hypertension in children
Current Opinion in Pediatrics, 2005Until recently, the diagnosis of idiopathic pulmonary arterial hypertension was virtually a death sentence, particularly for children. Although there is no cure for idiopathic pulmonary arterial hypertension, recent medical advances have dramatically changed the course of this disease in children.
Erika Berman, Rosenzweig, Robyn J, Barst
openaire +2 more sources
Idiopathic Pulmonary Arterial Hypertension in Childhood
Cardiology in Review, 2010The introduction of new medicines to treat pulmonary vascular disease has renewed interest in the management of children with idiopathic pulmonary arterial hypertension. We now have a practical classification of pulmonary hypertension, improved diagnostic techniques, and internationally recognized diagnostic and management guidelines.
openaire +2 more sources
Idiopathic pulmonary arterial hypertension with coexisting CHD
Cardiology in the Young, 2018AbstractSinus venosus atrial septal defect can result in an increase in pulmonary blood flow and vascular resistance, leading to pulmonary hypertension. Rarely, the degree of pulmonary hypertension is out of proportion to the degree of intra-cardiac shunting.
Thomas G. Day +2 more
openaire +2 more sources
Iron Deficiency in Patients With Idiopathic Pulmonary Arterial Hypertension
Heart, Lung and Circulation, 2014Iron deficiency has been reported to be highly prevalent in idiopathic pulmonary arterial hypertension (iPAH) patients, with the potential to influence cardiac performance, pulmonary artery pressures and the pulmonary vascular response to hypoxia.Iron status was evaluated in 29 iPAH patients, and was related to haemodynamic, echocardiographic and ...
van Empel, Vanessa P M +3 more
openaire +3 more sources
Pulmonary Artery Denervation for Idiopathic Pulmonary Arterial Hypertension: A Case Report
Catheterization and Cardiovascular InterventionsABSTRACT Pulmonary arterial hypertension (PAH) is a life‐threatening condition characterized by significantly elevated pulmonary artery pressure (PAP) and resistance. While targeted drugs can alleviate symptoms, their long‐term efficacy is limited, and treatment is often associated with notable side effects and financial burden ...
Gou Junqi +5 more
openaire +2 more sources